ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Bladder Cancer

Bladder Cancer

Use of the diabetes drug pioglitazone was not associated with a significantly increased risk of bladder cancer, in a large cohort study.

A 65-year-old woman presented to a local emergency department complaining of right flank pain that had worsened over the past 10 days. A CT scan of the abdomen and pelvis showed intravesical tumors of the urinary bladder.

Advanced bladder cancer patients with poor prognosis appear to benefit from adding apatorsen 600 mg to first-line chemotherapy with gemcitabine/cisplatin.

Pembrolizumab demonstrates durable antitumor activity in patients with advanced urothelial cancer, with a higher response rate seen in patients with PD-L1 expression.

Presentation with a urinary tract infection delayed a bladder cancer diagnosis among a population of Medicare patients, with worse delays experienced by women.

Phase II study results found that half of patients with relapsed or refractory urothelial carcinoma responded to treatment with pazopanib and paclitaxel.

In this interview we discuss the changing landscape of systemic therapies for the treatment of bladder cancer.

Pages

Subscribe to Bladder Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.